Compare BCC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCC | ARQT |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | 7680 | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | 2012 | 2020 |
| Metric | BCC | ARQT |
|---|---|---|
| Price | $75.84 | $26.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $99.20 | $34.00 |
| AVG Volume (30 Days) | 406.5K | ★ 1.8M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $4,995,290,000.00 | $376,072,000.00 |
| Revenue This Year | $3.41 | $34.85 |
| Revenue Next Year | $4.76 | $29.39 |
| P/E Ratio | $155.26 | ★ N/A |
| Revenue Growth | 12.71 | ★ 91.34 |
| 52 Week Low | $65.00 | $13.06 |
| 52 Week High | $95.00 | $31.77 |
| Indicator | BCC | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 61.15 |
| Support Level | $71.49 | $24.81 |
| Resistance Level | $78.96 | $27.26 |
| Average True Range (ATR) | 2.89 | 1.21 |
| MACD | 0.74 | 0.05 |
| Stochastic Oscillator | 61.23 | 58.97 |
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.